MIM
ASND icon

Monashee Investment Management’s Ascendis Pharma A/S ASND Stock Holding History

Monashee Investment Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$1.49M – 42
2024
Q3 		$1.49M Buy
+10,000
New +$1.35M 0.16% 81
2019
Q2 		– Sell
-15,500
Closed -$1.82M – 165
2019
Q1 		$1.82M Buy
+15,500
New +$1.36M 0.42% 67
2017
Q3 		– Hold
0
– – – 36

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Monashee Investment Management's ASND Position: Q4 2024 in Review

Monashee Investment Management sold out of Ascendis Pharma A/S (ASND) in Q4 2024, closing a stake of 10,000 shares — an estimated $1.49M sold.

Monashee Investment Management first reported a position in ASND in Q1 2019 and held it in 2 quarters. The position peaked at $1.82M in Q1 2019. 214 funds tracked by Wall St. Rank hold ASND as of Q4 2024.

  • Monashee Investment Management reported no remaining Ascendis Pharma A/S position as of Q4 2024 after selling out during the quarter.
  • Monashee Investment Management sold 10,000 Ascendis Pharma A/S shares in Q4 2024, an estimated $1.49M.
  • Monashee Investment Management first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 2 quarters.
  • Monashee Investment Management's Ascendis Pharma A/S position peaked at $1.82M in Q1 2019.
  • 214 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2024.

Based on Monashee Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.